12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MultiStem: Additional Phase I data

Additional data from an open-label, dose-escalation Phase I trial in 36 patients showed that a single injection of the highest dose of IV MultiStem given following allogeneic hematopoietic stem cell transplant (HSCT) led to a 100-day cumulative incidence of moderate to severe acute GvHD of 11%, which Athersys said "compares favorably" with historical clinical experience for this patient population (40-60% incidence rate for grade II-IV GvHD for historical control). No patient developed severe GvHD and there were no graft failures over the 100-day period following HSCT. Furthermore, relapse-free survival at...

Read the full 429 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >